Mizokami Masashi, Kusumoto Shigeru
Genome Medical Sciences Project, Research Institute, National Center for Global Health and Medicine.
Department of Hematology & Oncology, Nagoya City University Graduate School of Medical Sciences.
Rinsho Ketsueki. 2019;60(9):1401-1407. doi: 10.11406/rinketsu.60.1401.
Viral hepatitis during and after hematological disease treatment is a fatal complication and is mostly caused by HBV reactivation among HBV carriers and their pre-existing infected person. In this study, the authors review the current status of HBV reactivation, HBV pathogenesis, and implications of molecularly targeted drugs as a risk factor in the context of hematological conditions and detail the current HBV reactivation preventive strategy based on referred risk factors. Additionally, the recently clarified significance of HBV antibody titer as a preventive factor of HBV reactivation and the discovery and significance of BTNL2 as a novel host factor inducing high HBV antibody levels have also been described, as well as the applicability of an HBV vaccine in prevention of HBV reactivation. By clarifying research questions that should be addressed as soon as possible, the authors aim to establish an HBV reactivation preventive strategy.
血液系统疾病治疗期间及之后的病毒性肝炎是一种致命并发症，主要由乙肝病毒携带者及其既往感染者中的乙肝病毒再激活引起。在本研究中，作者回顾了乙肝病毒再激活的现状、乙肝病毒发病机制以及分子靶向药物作为血液系统疾病背景下的危险因素的影响，并根据相关危险因素详细阐述了当前乙肝病毒再激活的预防策略。此外，还描述了最近明确的乙肝病毒抗体滴度作为乙肝病毒再激活预防因素的意义，以及作为诱导高乙肝病毒抗体水平的新型宿主因子BTNL2的发现及其意义，以及乙肝疫苗在预防乙肝病毒再激活中的适用性。通过明确应尽快解决的研究问题，作者旨在建立一种乙肝病毒再激活预防策略。
